ĐẶC ĐIỂM HÌNH ẢNH CHỤP CẮT LỚP VI TÍNH VÀ KẾT QUẢ ĐIỀU TRỊ NÚT MẠCH HÓA CHẤT UNG THƯ BIỂU MÔ TẾ BÀO GAN

Abstract

Background: Hepatocellular carcinoma is a common malignancy. Transarterial chemoembolization is an important treatment modality, while computed tomography and the mRECIST criteria are useful for monitoring treatment response. Objective: To describe computed tomography imaging characteristics and evaluate treatment outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma. Materials and methods: A crosssectional descriptive study was conducted on 35 patients with hepatocellular carcinoma at Can Tho Central General Hospital from June 2025 to January 2026. Results: Tumors were most commonly located in liver segments VIII, VII, and VI, accounting for 57.1%, 42.9%, and 31.4%, respectively. The most common tumor size was 20-50 mm, accounting for 51.4%. Multifocal tumors predominated, with three tumors being the most frequent pattern, accounting for 60.0%. On computed tomography, tumors were mainly hypodense on non-contrast images, accounting for 77.2%, showed strong arterial phase enhancement, and demonstrated washout in the portal venous or delayed phase in 88.6% of cases. Tumor neovascularity was observed in 37.1% of cases, the feeding artery was mainly intrahepatic in 80.0%, and portal vein thrombosis was present in 20.0%. After 6 months, complete response, partial response, stable disease, and progressive disease according to mRECIST were observed in 31.4%, 40.0%, 25.7%, and 2.9% of patients, respectively. Conclusions: In this study, hepatocellular carcinoma was commonly located in the posterior segments of the right hepatic lobe and showed typical computed tomography features of arterial phase enhancement and washout. After 6 months, most patients achieved favorable responses according to mRECIST, suggesting that transarterial chemoembolization is an effective treatment modality in appropriately selected patients.